Cargando…
Loxapine in patient with clozapine-resistant psychosis
Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozap...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
College of Psychiatric & Neurologic Pharmacists
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287867/ https://www.ncbi.nlm.nih.gov/pubmed/34316424 http://dx.doi.org/10.9740/mhc.2021.07.263 |
_version_ | 1783723992191860736 |
---|---|
author | Erley, Jennifer Goldsborough, Sarah VandenBerg, Amy Audu, Alexandra |
author_facet | Erley, Jennifer Goldsborough, Sarah VandenBerg, Amy Audu, Alexandra |
author_sort | Erley, Jennifer |
collection | PubMed |
description | Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozapine in both structure and receptor binding. This case describes a 57-year-old male with a history of severe paranoid schizophrenia despite treatment with clozapine and other psychotropic agents, who experienced clinical improvement after a cross titration from clozapine to loxapine. Loxapine may be a reasonable alternative in patients with treatment-refractory schizophrenia who do not tolerate or respond to clozapine. |
format | Online Article Text |
id | pubmed-8287867 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | College of Psychiatric & Neurologic Pharmacists |
record_format | MEDLINE/PubMed |
spelling | pubmed-82878672021-07-26 Loxapine in patient with clozapine-resistant psychosis Erley, Jennifer Goldsborough, Sarah VandenBerg, Amy Audu, Alexandra Ment Health Clin Case Reports Clozapine is recognized as the drug of choice for treatment-refractory schizophrenia, but use may be limited because of strict monitoring requirements and adverse effects including severe neutropenia, seizures, and myocarditis. Loxapine is a first-generation antipsychotic with similarities to clozapine in both structure and receptor binding. This case describes a 57-year-old male with a history of severe paranoid schizophrenia despite treatment with clozapine and other psychotropic agents, who experienced clinical improvement after a cross titration from clozapine to loxapine. Loxapine may be a reasonable alternative in patients with treatment-refractory schizophrenia who do not tolerate or respond to clozapine. College of Psychiatric & Neurologic Pharmacists 2021-07-16 /pmc/articles/PMC8287867/ /pubmed/34316424 http://dx.doi.org/10.9740/mhc.2021.07.263 Text en © 2021 CPNP. The Mental Health Clinician is a publication of the College of Psychiatric and Neurologic Pharmacists. https://creativecommons.org/licenses/by-nc/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial 3.0 License, which permits non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Case Reports Erley, Jennifer Goldsborough, Sarah VandenBerg, Amy Audu, Alexandra Loxapine in patient with clozapine-resistant psychosis |
title | Loxapine in patient with clozapine-resistant psychosis |
title_full | Loxapine in patient with clozapine-resistant psychosis |
title_fullStr | Loxapine in patient with clozapine-resistant psychosis |
title_full_unstemmed | Loxapine in patient with clozapine-resistant psychosis |
title_short | Loxapine in patient with clozapine-resistant psychosis |
title_sort | loxapine in patient with clozapine-resistant psychosis |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8287867/ https://www.ncbi.nlm.nih.gov/pubmed/34316424 http://dx.doi.org/10.9740/mhc.2021.07.263 |
work_keys_str_mv | AT erleyjennifer loxapineinpatientwithclozapineresistantpsychosis AT goldsboroughsarah loxapineinpatientwithclozapineresistantpsychosis AT vandenbergamy loxapineinpatientwithclozapineresistantpsychosis AT audualexandra loxapineinpatientwithclozapineresistantpsychosis |